Search results for "VIM-1"

showing 2 items of 2 documents

A novel VIM‐type metallo‐beta‐lactamase (VIM‐14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit

2011

AbstractA Pseudomonas aeruginosa highly resistant to carbapenems was isolated in a neonatal intensive care unit in Palermo, Italy. The strain was found to carry a novel VIM‐type enzyme, classified as VIM‐14. The novel enzyme differs from VIM‐4 in a G31S mutation. VIM‐14 was harboured in a class 1 integron with a new organization. The integron carried the genes aac7, blaVIM‐14, blaOXA‐20 and aac4 in that order.

DNA BacterialMicrobiology (medical)Settore MED/07 - Microbiologia E Microbiologia ClinicaNeonatal intensive care unitSettore MED/17 - Malattie Infettivemetallo-b-lactamaseAntibiotic resistancemetallo-β-lactamasemedicine.medical_treatmentMolecular Sequence DataMicrobial Sensitivity TestsBiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeIntegronbeta-LactamasesIntegronscarbapenemlaw.inventionMicrobiologyAntibiotic resistancelawDrug Resistance Multiple BacterialIntensive Care Units Neonatalpolycyclic compoundsmedicineHumansVIM-14Antibacterial agentBase SequencePseudomonas aeruginosaInfant Newbornmetallo‐β‐lactamaseAntibiotic resistance; carbapenems; metallo-b-lactamase; Pseudomonas aeruginosa; VIM-14Sequence Analysis DNAGeneral Medicinebiochemical phenomena metabolism and nutritionbacterial infections and mycosesbiology.organism_classificationIntensive care unitInfectious DiseasesPseudomonas aeruginosaBeta-lactamasebiology.proteinbacteriacarbapenemsVIM‐14PseudomonadaceaeClinical Microbiology and Infection
researchProduct

Combination of aztreonam, ceftazidime–avibactam and amikacin in the treatment of VIM-1 Pseudomonas aeruginosa ST235 osteomyelitis

2021

Abstract We describe a challenging case of patient with metallo-beta-lactamase-producing Pseudomonas aeruginosa sternal osteomyelitis following aortic valve replacement with biological prosthesis. The strain exhibited a multidrug-resistance phenotype carrying the blaVIM-1 gene and belonged to the high-risk clone sequence type ST235. The patient was successfully treated with surgical debridement plus antibiotic therapy with ceftazidime/avibactam, aztreonam, and amikacin. Time-kill curves showed that this triple antibiotic combination at 1 × MIC was strongly synergic after 8 h, achieving 99.9% killing and maintaining this until 48 h.

Microbiology (medical)AvibactamDrug ResistanceCeftazidimeInfectious and parasitic diseasesRC109-216Aztreonammedicine.disease_causeST235CeftazidimeMicrobiologyCeftazidime–avibactamchemistry.chemical_compoundAztreonamAortic valve replacementDrug TherapyDrug Resistance Multiple BacterialmedicineHumansPseudomonas InfectionsPseudomonas aeruginosa; ST235; VIM-1; aztreonam; ceftazidime-avibactam; osteomyelitisAmikacinAgedPseudomonas aeruginosabusiness.industryceftazidime-avibactamOsteomyelitisBacterialOsteomyelitisGeneral MedicineCeftazidime/avibactammedicine.diseaseAnti-Bacterial AgentsDrug CombinationsInfectious DiseaseschemistryDebridementAmikacinPseudomonas aeruginosaCombinationVIM-1Drug Therapy CombinationFemalebusinessAzabicyclo CompoundsMultiplemedicine.drug
researchProduct